Multiple MNC Executives Affirm Continued Investment in China Market Amid New Product Launches and Expanded Operations

Source: @CNBC-China Weibo

[#Multiple MNC Executives Say They Will Continue to Increase Investment in the Chinese Market#] [#Take You to Explore the CIIE#] On November 5, the eighth China International Import Expo (CIIE) opened in Shanghai. Blue Whale News learned that several globally leading pharmaceutical companies, including MSD, AstraZeneca, Novo Nordisk, Eli Lilly, and Gilead Sciences, have showcased advanced innovative therapies across various disease areas worldwide. Multiple executives expressed their intention to continue increasing investment in the Chinese market. AstraZeneca has added an investment of approximately $136 million to expand the production capacity of its Qingdao supply base. Gilead Sciences will present two products making their Asian debut: Lenacapavir, a long-acting HIV pre-exposure prophylaxis drug, and Seladelpar for primary biliary cholangitis (PBC), along with showcasing 13 innovative drugs launched in China. MSD is displaying about 30 approved drugs and vaccines within China. Eli Lilly has set up interactive experience zones such as the "Memory Café" and "Body Resistance Decoding Exhibition" to raise public awareness. Novo Nordisk is presenting several products from the "Semaglutide Family." (Blue Whale News)